{
    "2020-12-28": [
        [
            {
                "time": "",
                "original_text": "医药生物行业跨市场周报：融合与共生  重视药店板块回调后的配置价值",
                "features": {
                    "keywords": [
                        "医药生物",
                        "跨市场",
                        "药店板块",
                        "回调",
                        "配置价值"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "金额高达76亿！蓝帆医疗的商誉会在2020年引爆吗？",
                "features": {
                    "keywords": [
                        "蓝帆医疗",
                        "商誉",
                        "76亿",
                        "2020年"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}